Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
Status:
Completed
Trial end date:
2015-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of long-term treatment with
alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to
diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy,
and α-glucosidase inhibitor.
In addition, examining the safety and efficacy of alogliptin in patients with renal
impairment, information on the appropriate dosage of alogliptin according to the severity of
impaired renal function should be collected.